Skip to main content

Advertisement

Table 2 Summary of the sensitivity and specificity for T790 M mutation testing based on various plasma assay platforms

From: Third generation EGFR TKIs: current data and future directions

Plasma Assays Sensitivity n/N (%) Specificity n/N (%) Plasma T790 M positive / histology negative (%) Reference
EGFR T790 M after PD on TKI EGFR T790 M after PD on TKI
Digital PCR, Microdroplet BEAMing 49/60 (81.7) 33/45 (73.3) 2/3 (66.7) 9/18 (50) 9/18 (50) Karlovich 2016 (Roci)
43/51 (84.3) 33/41 (80.5) 65/67 (97.0) 14/24 (58.3) 10/24 (41.7) Thress 2015 (AURA)
112/136 (82.3) 111/158 (70.3) 78/80 (97.5) 40/58 (69.0) 18/40 (31.0) Oxnard 2016
ddPCR NA 6/9 (66.7) NA 5/7 (71.4) 2/7 (28.6) Wang 2017
25/33 (75.7) 20/31 (64.5) 7/8 (87.5) 7/10 (70) 3/10 (30) Takahama 2016 (West Japan Oncology Group)
9/10 (90) 12/17 (70.5) 28/28 (100) 5/6 (83.3) 1/6 (16.7) Thress 2015 (AURA)
Allele -specific PCR ARMS, Therascreen 30/37 (81.1) 5/17 (29.4) 38/38 (100) 6/6 (100) 0 Thress 2015 (AURA)
Roche cobas® AS-PCR 43/51 (84.3) 30/41 (73.2) 65/67 (97.0) 16/24 (66.7) 8/24 (33.3) Thress 2015 (AURA)
55/75 (73.3) 21/33 (63.6) 24/24 (100) 61/62 (98.4) 1/62 (1.6) Karlovich et al. 2016 (Roci)
NA 254/414 (61.3) NA 99/126 (78.6) 27/126 (21.4) Jenkins 2017 (AURA ext. + AURA2 pooled), excluded those with unknown plasma results
13/16 (81.2) 6/10 (60.0) 30/30 (100) 9/15 (60) 6/15 (40) Sundaresan 2016
CTCs NA 5/9 (55.5) NA 7/12 (58.2) 5/12 (41.7) Sundaresan 2016